Clinical Nurse Specialist Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kimberly Slusser

Clinical Nurse Specialist, Adult Health Walnut Ridge, AR Clinical Nurse Specialist

NPI 1457905465 CMS profile 11062515

201 Colonial Dr, Walnut Ridge, AR 72476

Open in the dashboard

General payments

$363

16 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Slusser of Walnut Ridge, AR is reported in the CMS Open Payments database as having received $363 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $128 3
2024 General $94 6
2023 General $122 6
2022 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Slusser
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Kimberly Slusser were reported at $128. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Kimberly Slusser Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $48–$445 $132
2022 $18 $163 $57–$526 $149
2023 $122 $173 $64–$597 $160
2024 $94 $171 $54–$575 $164
2025 $128 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $86 1 payment
  2. Pfizer Inc. $77 4 payments
  3. Xeris Pharmaceuticals, Inc. $58 3 payments
  4. AbbVie, Inc. $56 3 payments
  5. GlaxoSmithKline, LLC. $34 2 payments
  6. AstraZeneca Pharmaceuticals LP $33 2 payments
  7. Medtronic, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $363 16 payments
Products named General payments · program years 2022–2025
  1. Ozempic $86 1 payment
  2. PREMARIN $77 4 payments
  3. ESTRING $60 3 payments
  4. VRAYLAR $42 2 payments
  5. TRELEGY ELLIPTA $34 2 payments
  6. AIRSUPRA $33 2 payments
  7. GVOKE HYPOPEN $33 2 payments
  8. KEVEYIS $25 1 payment
  9. PAXLOVID $22 1 payment
  10. INTELLIS ADAPTIVESTIM $19 1 payment
  11. Other $46 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 130 drugs

Part D claims

5,879

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$488,534

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

24.3%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 51 $77,639
Jardiance Empagliflozin Brand 54 $52,879
Farxiga Dapagliflozin Propanediol Brand 73 $48,252
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $43,384
Eliquis Apixaban Brand 54 $35,756
Ozempic Semaglutide Brand 33 $33,111
Tresiba Flextouch U-200 Insulin Degludec Brand 12 $28,007
Januvia Sitagliptin Phosphate Brand 20 $19,056
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 16 $15,740
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 24 $12,851

The 10 drugs with the highest cost, of 130 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$4,810

Medicare's payments for the services billed

Medicare patients

65

Average age 69

Services billed

442

41 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 31%
COPD 25%
Depression 22%
Ischemic heart disease 18%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $33
$33 — —
VRAYLAR
  • AbbVie, Inc. $14
$14 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $14
$14 — —
DUAVEE
  • PFIZER INC. $5
$5 — —
PREMARIN
  • PFIZER INC. $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record